Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN II 3.5% M IN PLASTIC CONTAINER vs AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% M is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral/enteral nutrition. The 'M' formulation includes electrolytes and trace elements. Amino acids are incorporated into endogenous proteins, serving as substrates for gluconeogenesis, oxidative metabolism, and neurotransmitter synthesis.
Aminosyn II 5% with electrolytes in dextrose 25% provides amino acids for protein synthesis, dextrose for caloric supply, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
Intravenous administration; typical adult dose is 1 to 2 g amino acids/kg/day, corresponding to 30 to 60 mL/kg/day of 3.5% solution; infusion rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous; initial adult dose 1.0 g/kg/day of amino acids, up to 1.5 g/kg/day; dextrose rate 5 mg/kg/min initially, titrate to 7 mg/kg/min; daily dose adjusted based on metabolic requirements, electrolytes as per serum levels.
None Documented
None Documented
Variable; amino acids have short plasma half-lives (minutes to hours) due to rapid cellular uptake and metabolism; no meaningful terminal half-life for the mixture.
Not applicable as a single entity; component amino acids have half-lives ranging from minutes (e.g., alanine) to hours (e.g., branched-chain amino acids); dextrose half-life ~1.5-2 hours in normal glucose metabolism; clinical context: continuous infusion maintains steady state.
100% renal; amino acids are deaminated and metabolized to urea, which is excreted renally; minimal (<1%) biliary/fecal excretion.
Renal: amino acids and dextrose metabolites excreted primarily as urea, CO2, and water; electrolytes excreted renally with fractional excretion varying by individual needs; no significant biliary or fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution